Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.60    -0.05 (-1.08%)
Bid:
4.55
Ask:
4.615
Spread: 0.065 (1.429%)
Market Cap: £220.78m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

Board Changes

27 Mar 2025 07:11

RNS Number : 4695C
Seeing Machines Limited
27 March 2025
 

 

Seeing Machines Limited ("Seeing Machines" or the "Company")

 

 

27 March 2025

 

Board Changes

 

Seeing Machines Limited (AIM: SEE, "Seeing Machines" or the "Company"), the advanced computer vision technology company that designs AI-powered operator monitoring systems to improve transport safety, announces that Michael Brown, a non-executive director of the Seeing Machines board since 2020 and a member of the People, Culture and Remuneration Committee, will be stepping down as a director of the Company with effect from today.

 

Mr Brown was the nominee director for a major shareholder, Lombard Odier, and his resignation coincides with the shareholding of Lombard Odier falling below 10% after the recent introduction of Mitsubishi Electric Mobility Corporation (MELMB) onto the Company's share register.

 

With the resignation of Mr Brown, the remaining non-executive directors are all considered to be independent directors. At this stage the Board does not propose to appoint another director. Mr Stephane Vedie will become a member of the People, Culture and Remuneration Committee.

 

Kate Hill, Chair of Seeing Machines, commented: "On behalf of my fellow Board members I'd like to thank Michael for his unwavering support of the Company and advice throughout his tenure. His insight and observations have been extremely helpful in navigating the past 5 years. Michael leaves the Board at a time when the Company has funding in place beyond the point at which we expect to become self-financing. We will continue to work with Michael and his colleagues at Lombard Odier, our second largest shareholder, and remain grateful for their support. I know they, like us, believe the upcoming regulations will represent a key moment in the Company's journey."

 

 

Enquiries:

 

Seeing Machines Limited

+61 2 6103 4700

Paul McGlone - CEO

Sophie Nicoll - Corporate Communications

 

 

 

Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

+44 20 7710 7600

Alex Price

Fred Walsh

Ben Good

Sarah Wong

 

 

 

DGA Group (Media Enquiries)

James StylesMethuselah TanyanyiwaMatthias Jarosz

seeingmachines@dgagroup.com

+44 20 7664 5095

 

 

 

 

 

About Seeing Machines (AIM: SEE), a global company founded in 2000 and headquartered in Australia, is an industry leader in vision-based monitoring technology that enable machines to see, understand and assist people. Seeing Machines' technology portfolio of AI algorithms, embedded processing and optics, power products that need to deliver reliable real-time understanding of vehicle operators. The technology spans the critical measurement of where a driver is looking, through to classification of their cognitive state as it applies to accident risk. Reliable "driver state" measurement is the end-goal of Driver Monitoring Systems (DMS) technology. Seeing Machines develops DMS technology to drive safety for Automotive, Commercial Fleet, Off-road and Aviation. The company has offices in Australia, USA, Europe and Asia, and supplies technology solutions and services to industry leaders in each market vertical.

 

www.seeingmachines.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAPKOBKOBKKQNB
Date   Source Headline
11th Mar 20097:00 amRNSReviewed Interim Results
18th Feb 20097:00 amRNSRestructuring of the business
28th Jan 20099:41 amRNSTrading update and notice of results
1st Dec 20088:14 amRNSChange of Registered Office
27th Nov 20088:08 amRNSResult of AGM
29th Oct 200810:52 amRNSNotice of AGM
23rd Sep 20087:00 amRNSFinal Results
17th Sep 20088:37 amRNSNotice of Final Results
26th Aug 20088:33 amRNSNEW FACEAPI PRODUCT RELEASE
23rd Jul 20087:37 amRNSFirst Expected Profit Report
7th May 20088:08 amRNSNORTH AMERICAN OPERATION
7th Apr 200812:00 pmRNSChange of Broker
4th Mar 20087:59 amRNSInterim Results
4th Mar 20087:51 amRNSMajor contract gain
13th Feb 20088:27 amRNSHolding in Company
28th Dec 20079:11 amRNSAnnual Report
11th Dec 200710:54 amRNSChange of Adviser
29th Nov 200710:03 amRNSAGM Results
8th Nov 200712:38 pmRNSDirector/PDMR Shareholding
8th Nov 200712:34 pmRNSGlaucoma Device at AAO
31st Oct 20079:26 amRNSCompletion of Placing-Replace
31st Oct 20077:01 amRNSCompletion of Placing
26th Oct 20079:35 amRNSShareholder Approval
17th Oct 20072:21 pmRNSDirector/PDMR Shareholding
15th Oct 20079:23 amRNSCFO Appointment
25th Sep 200710:23 amRNSFurther Placing
24th Sep 20071:12 pmRNSFinal Results
24th Sep 20071:00 pmRNSFundraising
15th Aug 200712:43 pmRNSAIM Rule 26 Compliance
15th Aug 20079:27 amRNSFDA Approval for Truefield
2nd Jul 20077:01 amRNSNew Product Releases
29th Jun 200710:11 amRNSMaster License Agreement
22nd May 200711:15 amRNSLicensing agreement signed
8th May 20077:02 amRNSGlaucoma Device Demonstrated
28th Mar 20072:40 pmRNSInterim Results
14th Mar 200710:45 amRNSAward win for glaucoma device
12th Mar 20077:02 amRNSAddition to product released
19th Dec 200610:06 amRNSTotal Voting Rights
30th Nov 20068:27 amRNSAGM Statement
9th Nov 20067:01 amRNSGlaucoma Study Re-commences
2nd Nov 20067:01 amRNSNew Product
19th Oct 20065:38 pmRNSFinal Results - Replacement
19th Oct 200611:29 amRNSFinal Results
18th Oct 200611:04 amRNSDirectorate Change
17th Oct 20063:20 pmRNSNew Version of faceLAB
21st Sep 20064:41 pmRNSIssue of Equity
18th Sep 200611:24 amRNSAutomotive progress
18th Sep 20069:45 amRNSGlaucoma Grant Signed
30th Aug 200611:46 amRNSClinical Study Results
14th Aug 200610:57 amRNSGrant Approval

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.